Benchmark analyst Matthew Harrigan raised the firm's price target on Lionsgate Studios to $17 from $15 and keeps a Buy rating on the shares after extending the firm's forecast another 24 months, through fiscal 2030, to better reflect the long-term dynamics for the business and accommodate concerns over comparisons post the "likely" two Michael releases and The Resurrection of the Christ films.
